Nigel Theobald, CEO of N4 Pharma commented: These results are another positive step forward for our Nuvec® delivery platform.
Canada becomes the second country in the world to legalise recreational marijuana
Canadian Prime Minister Justin Trudeau said Wednesday marijuana will be legal nationwide on October 17.
Eden Research plc (AIM:EDEN) TerpeneTech granted regulatory clearance for head-lice product
Sean Smith, Chief Executive Officer of Eden, said: “The development of this head-lice product has been in progress for approximately three years and it is good to see it
How Theranos CEO Elizabeth Holmes Committed Massive Fraud
Infamous blood testing company Theranos is shutting down — look back at some of the top revelations about its demise
Midatech Pharma PLC (AIM:MTPH) Interim results from MTD201 exploratory study
Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and Q-Sphera™ Microsphere Technology
David Smith, Chief Operating Officer of Flying Brands Ltd (LON:FBDU) Interview
Zak Mir talks with David Smith about his new appointment and he talks about the background of the business.
OKYO Pharma Limited (LSE:OKYO) Annual Report and Notice of AGM
Annual Report and Accounts and Notice of Annual General Meeting
Kin Group PLC (AIM:KIN) Bidstack Limited – Transaction update – RTO
Kin Group Plc (“Kin” or “the Company”) Bidstack Limited (“Bidstack”) – Transaction update The Directors of Kin are pleased to provide an update, further to the announcement on 5
Abzena PLC (AIM:ABZA) Recommended Cash Offer for Abzena plc
Astro Bidco Limited, a company wholly-owned by WCAS XII-Astro, L.P.
Feedback plc (AIM:FDBK) First GE Healthcare order for TexRAD® medical imaging software
Feedback plc (AIM: FDBK, “Feedback” or the “Company”), the specialist medical imaging technology company, announces that its operating company Feedback Medical Ltd has received its first order via GE
SalvaRx Group plc (AIM:SALV) Proposed disposal of interest in SalvaRx Limited
SalvaRx Group plc (AIM: SALV), a biotechnology company focused on discovering and developing immunotherapies for cancer, announces that it has entered into a conditional sale agreement (the “Sale Agreement”)
